Torsades de pointes (TdP) is a type of ventricular arrhythmia that can lead to sudden cardiac death. Drug-induced TdP has been an important concern for researchers and international regulatory boards. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative was proposed that integrates in vitro testing and computational models of cardiac ion channels and human cardiomyocyte cells to evaluate the proarrhythmic risk of drugs. The TdP risk classification performance using only a single TdP metric may require some improvements because of information limitations and the instability of generalizing results. This study evaluates the performance of TdP metrics from the in silico simulations of the Tomek-O'Hara Rudy (ToR-ORd) ventricular cell model for classifying the TdP risk of drugs. We utilized these metrics as an input to an artificial neural network (ANN)-based classifier. The ANN model was optimized through hyperparameter tuning using the grid search (GS) method to find the optimal model. The study outcomes show an area under the curve (AUC) value of 0.979 for the high-risk category, 0.791 for the intermediate-risk category, and 0.937 for the low-risk category. Therefore, this study successfully demonstrates the capability of the ToR-ORd ventricular cell model in classifying the TdP risk into three risk categories, providing new insights into TdP risk prediction methods.
Introduction: Predicting ventricular arrhythmia Torsade de Pointes (TdP) caused by drug-induced cardiotoxicity is essential in drug development. Several studies used single biomarkers such as qNet and Repolarization Abnormality (RA) in a single cardiac cell model to evaluate TdP risk. However, a single biomarker may not encompass the full range of factors contributing to TdP risk, leading to divergent TdP risk prediction outcomes, mainly when evaluated using unseen data. We addressed this issue by utilizing multi-in silico features from a population of human ventricular cell models that could capture a representation of the underlying mechanisms contributing to TdP risk to provide a more reliable assessment of drug-induced cardiotoxicity. Method: We generated a virtual population of human ventricular cell models using a modified O'Hara-Rudy model, allowing inter-individual variation. IC50 and Hill coefficients from 67 drugs were used as input to simulate drug effects on cardiac cells. Fourteen features (dVmdtrepol, dVmdtmax, Vmpeak, Vmresting, APDtri, APD90, APD50, Capeak, Cadiastole, Catri, CaD90, CaD50, qNet, qInward) could be generated from the simulation and used as input to several machine learning models, including k-nearest neighbor (KNN), Random Forest (RF), XGBoost, and Artificial Neural Networks (ANN). Optimization of the machine learning model was performed using a grid search to select the best parameter of the proposed model. We applied five-fold cross-validation while training the model with 42 drugs and evaluated the model's performance with test data from 25 drugs. Result: The proposed ANN model showed the highest performance in predicting the TdP risk of drugs by providing an accuracy of 0.923 (0.908-0.937), sensitivity of 0.926 (0.909-0.942), specificity of 0.921 (0.906-0.935), and AUC score of 0.964 (0.954-0.975). Discussion and conclusion: According to the performance results, combining the electrophysiological model including inter-individual variation and optimization of machine learning showed good generalization ability when evaluated using the unseen dataset and produced a reliable drug-induced TdP risk prediction system.
Due to the outbreak of the SARS-CoV-2 virus, drug repurposing and Emergency Use Authorization have been proposed to treat the coronavirus disease 2019 (COVID-19) during the pandemic. While the efficiency of the drugs has been discussed, it was identified that certain compounds, such as chloroquine and hydroxychloroquine, cause QT interval prolongation and potential cardiotoxic effects. Drug-induced cardiotoxicity and QT prolongation may lead to life-threatening arrhythmias such as torsades de pointes (TdP), a potentially fatal arrhythmic symptom. Here, we evaluated the risk of repurposed pyronaridine or artesunate-mediated cardiac arrhythmias alone and in combination for COVID-19 treatment through in vitro and in silico investigations using the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. The potential effects of each drug or in combinations on cardiac action potential (AP) and ion channels were explored using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and Chinese hamster ovary (CHO) cells transiently expressing cardiac ion channels (Nav1.5, Cav1.2, and hERG). We also performed in silico computer simulation using the optimized O'Hara-Rudy human ventricular myocyte model (ORd model) to classify TdP risk. Artesunate and dihydroartemisinin (DHA), the active metabolite of artesunate, are classified as a low risk of inducing TdP based on the torsade metric score (TMS). Moreover, artesunate does not significantly affect the cardiac APs of hiPSC-CMs even at concentrations up to 100 times the maximum serum concentration (Cmax). DHA modestly prolonged at APD90 (10.16%) at 100 times the Cmax. When considering Cmax, pyronaridine, and the combination of both drugs (pyronaridine and artesunate) are classified as having an intermediate risk of inducing TdP. However, when considering the unbound concentration (the free fraction not bound to carrier proteins or other tissues inducing pharmacological activity), both drugs are classified as having a low risk of inducing TdP. In summary, pyronaridine, artesunate, and a combination of both drugs have been confirmed to pose a low proarrhythmogenic risk at therapeutic and supratherapeutic (up to 4 times) free Cmax. Additionally, the CiPA initiative may be suitable for regulatory use and provide novel insights for evaluating drug-induced cardiotoxicity.
Researchers commonly use continuous noninvasive blood-pressure measurement (cNIBP) based on photoplethysmography (PPG) signals to monitor blood pressure conveniently. However, the performance of the system still needs to be improved. Accuracy and precision in blood-pressure measurements are critical factors in diagnosing and managing patients' health conditions. Therefore, we propose a convolutional long short-term memory neural network (CNN-LSTM) with grid search ability, which provides a robust blood-pressure estimation system by extracting meaningful information from PPG signals and reducing the complexity of hyperparameter optimization in the proposed model. The multiparameter intelligent monitoring for intensive care III (MIMIC III) dataset obtained PPG and arterial-blood-pressure (ABP) signals. We obtained 75,226 signal segments, with 60,180 signals allocated for training data, 12,030 signals allocated for the validation set, and 15,045 signals allocated for the test data. During training, we applied five-fold cross-validation with a grid-search method to select the best model and determine the optimal hyperparameter settings. The optimized configuration of the CNN-LSTM layers consisted of five convolutional layers, one long short-term memory (LSTM) layer, and two fully connected layers for blood-pressure estimation. This study successfully achieved good accuracy in assessing both systolic blood pressure (SBP) and diastolic blood pressure (DBP) by calculating the standard deviation (SD) and the mean absolute error (MAE), resulting in values of 7.89 ± 3.79 and 5.34 ± 2.89 mmHg, respectively. The optimal configuration of the CNN-LSTM provided satisfactory performance according to the standards set by the British Hypertension Society (BHS), the Association for the Advancement of Medical Instrumentation (AAMI), and the Institute of Electrical and Electronics Engineers (IEEE) for blood-pressure monitoring devices.
This study proposes a convolutional neural network (CNN) model using action potential (AP) shapes as input for proarrhythmic risk assessment, considering the hypothesis that machine-learning features automatically extracted from AP shapes contain more meaningful information than do manually extracted indicators. We used 28 drugs listed in the comprehensive in vitro proarrhythmia assay (CiPA), consisting of eight high-risk, eleven intermediate-risk, and nine low-risk torsadogenic drugs. We performed drug simulations to generate AP shapes using experimental drug data, obtaining 2000 AP shapes per drug. The proposed CNN model was trained to classify the TdP risk into three levels, high-, intermediate-, and low-risk, based on in silico AP shapes generated using 12 drugs. We then evaluated the performance of the proposed model for 16 drugs. The classification accuracy of the proposed CNN model was excellent for high- and low-risk drugs, with AUCs of 0.914 and 0.951, respectively. The model performance for intermediate-risk drugs was good, at 0.814. Our proposed model can accurately assess the TdP risks of drugs from in silico AP shapes, reflecting the pharmacokinetics of ionic currents. We need to secure more drugs for future studies to improve the TdP-risk-assessment robustness.
Researchers have recently proposed the Comprehensive In-vitro Proarrhythmia Assay (CiPA) to analyze medicines' TdP risks. Using the TdP metric known as qNet, numerous single-drug effects have been studied to classify the medications as low, intermediate, and high-risk. Furthermore, multiple medication therapies are recognized as a potential method for curing patients, mainly when limited drugs are available. This work expands the TdP risk assessment of drugs by introducing a CiPA-based in silico analysis of the TdP risk of combined drugs. The cardiac cell model was simulated using the population of models approach incorporating drug-drug interactions (DDIs) models on several ion channels for various drug pairs. Action potential duration (APD90), qNet, and calcium duration (CaD90) were computed and analyzed as biomarker features. The drug combination maps were also used to illustrate combined medicines' TdP risk. We found that the combined drugs alter cell responses in terms of biomarkers such as APD90, qNet, and CaD90 in a highly nonlinear manner. The results also revealed that combinations of high-risk with low-risk and intermediate-risk with low-risk drugs could result in compounds with varying TdP risks depending on the drug concentrations.
Arrhythmias, Cardiac , Torsades de Pointes , Humans , Risk Assessment , Action Potentials , Myocytes, Cardiac , Drug Combinations
Hypertension is a severe public health issue worldwide that significantly increases the risk of cardiac vascular disease, stroke, brain hemorrhage, and renal dysfunction. Early screening of blood pressure (BP) levels is essential to prevent the dangerous complication associated with hypertension as the leading cause of death. Recent studies have focused on employing photoplethysmograms (PPG) with machine learning to classify BP levels. However, several studies claimed that electrocardiograms (ECG) also strongly correlate with blood pressure. Therefore, we proposed a concatenated convolutional neural network which integrated the features extracted from PPG and ECG signals. This study used the MIMIC III dataset, which provided PPG, ECG, and arterial blood pressure (ABP) signals. A total of 14,298 signal segments were obtained from 221 patients, which were divided into 9150 signals of train data, 2288 signals of validation data, and 2860 signals of test data. In the training process, five-fold cross-validation was applied to select the best model with the highest classification performance. The proposed concatenated CNN architecture using PPG and ECG obtained the highest test accuracy of 94.56-95.15% with a 95% confidence interval in classifying BP levels into hypotension, normotension, prehypertension, hypertension stage 1, and hypertension stage 2. The result shows that the proposed method is a promising solution to categorize BP levels effectively, assisting medical personnel in making a clinical diagnosis.
Action potential duration (APD) alternans, an alternating phenomenon between action potentials in cardiomyocytes, causes heart arrhythmia when the heart rate is high. However, some of the APD alternans observed in clinical trials occurs under slow heart rate conditions of 100 to 120 bpm, increasing the likelihood of heart arrhythmias such as atrial fibrillation. Advanced studies have identified the occurrence of this type of APD alternans in terms of electrophysiological ion channel currents in cells. However, they only identified physiological phenomena, such as action potential due to random changes in a particular ion channel's conductivity through ion models specializing in specific ion channel currents. In this study, we performed parameter sensitivity analysis via population modeling using a validated human ventricular physiology model to check the sensitivity of APD alternans to ion channel conductances. Through population modeling, we expressed the changes in alternans onset cycle length (AOCL) and mean APD in AOCL (AO meanAPD) according to the variations in ion channel conductance. Finally, we identified the ion channel that maximally affected the occurrence of APD alternans. AOCL and AO meanAPD were sensitive to changes in the plateau Ca2+ current. Accordingly, it was expected that APD alternans would be vulnerable to changes in intracellular calcium concentration.
The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have only looked at the effects of mexiletine on action potential duration (APD) or QT interval reduction. We further investigated mexiletine's effects on cardiac cells through simulations of single-cell (behavior of alternant occurrence) and 3D (with and without mexiletine). We discovered that mexiletine could shorten the cell's APD and change the alternant's occurrence to a shorter basic cycle length (BCL) between 350 and 420 ms. The alternant also appeared at a normal heart rate under the A1656D mutation. Furthermore, the 3D ventricle simulations revealed that mexiletine could reduce the likelihood of a greater spiral wave breakup in the A1656D mutant condition by minimizing the appearance of rotors. In conclusion, we found that mexiletine could provide extra safety features during therapy for LQT3 patients because it can change the alternant occurrence from a normal to a faster heart rate, and it reduces the chance of a spiral wave breakup. Therefore, these findings emphasize the promising efficacy of mexiletine in treating LQT3 patients under the A1656D mutation.
Since the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiation, many studies have suggested various in silico features based on ionic charges, action potentials (AP), or intracellular calcium (Ca) to assess proarrhythmic risk. These in silico features are computed through electrophysiological simulations using in vitro experimental datasets as input, therefore changing with the quality of in vitro experimental data; however, research to validate the robustness of in silico features for proarrhythmic risk assessment of drugs depending on in vitro datasets has not been conducted. This study aims to verify the availability of in silico features commonly used in assessing the cardiac toxicity of drugs through an ordinal logistic regression model and three in vitro datasets measured under different experimental environments and with different purposes. We performed in silico drug simulations using the Tomek-Ohara Rudy (ToR-ORD) ventricular myocyte model and computed 12 in silico features comprising six AP features, four Ca features, and two ion charge features, which reflected the effect and characteristics of each in vitro data for CiPA 28 drugs. We then compared the classific performances of ordinal logistic regressions according to these 12 in silico features and used in vitro datasets to validate which in silico feature is the best for assessing the proarrhythmic risk of drugs at high, intermediate, and low levels. All 12 in silico features helped determine high-risky torsadogenic drugs, regardless of the in vitro datasets used in the in silico simulation as input. In the three types of in silico features, AP features were the most reliable for determining the three Torsade de Pointes (TdP) risk standards. Among AP features, AP duration at 50% repolarization (APD50) was the best when individually using in silico features per in vitro dataset. In contrast, the AP repolarization velocity (dVm/dtMax_repol) was the best when merging all in silico features computed through three in vitro datasets.
Comprehensive in vitro Proarrhythmia Assay (CiPA) projects for assessing proarrhythmic drugs suggested a logistic regression model using qNet as the Torsades de Pointes (TdP) risk assessment biomarker, obtained from in silico simulation. However, using a single in silico feature, such as qNet, cannot reflect whole characteristics related to TdP in the entire action potential (AP) shape. Thus, this study proposed a deep convolutional neural network (CNN) model using differential action potential shapes to classify three proarrhythmic risk levels: high, intermediate, and low, considering both characteristics related to TdP not only in the depolarization phase but also the repolarization phase of AP shape. We performed an in silico simulation and got AP shapes with drug effects using half-maximal inhibitory concentration and Hill coefficients of 28 drugs released by CiPA groups. Then, we trained the deep CNN model with the differential AP shapes of 12 drugs and tested it with those of 16 drugs. Our model had a better performance for classifying the proarrhythmic risk of drugs than the traditional logistic regression model using qNet. The classification accuracy was 98% for high-risk level drugs, 94% for intermediate-risk level drugs, and 89% for low-risk level drugs.
Torsades de Pointes , Computer Simulation , DNA-Binding Proteins , Humans , Neural Networks, Computer , Risk Assessment , Torsades de Pointes/chemically induced
While previous studies have demonstrated the feasibility of using ear-electroencephalography (ear-EEG) for the development of brain-computer interfaces (BCIs), most of them have been performed using exogenous paradigms in offline environments. To verify the reliable feasibility of constructing ear-EEG-based BCIs, the feasibility of using ear-EEG should be further demonstrated using another BCI paradigm, namely the endogenous paradigm, in real-time online environments. Exogenous and endogenous BCIs are to use the EEG evoked by external stimuli and induced by self-modulation, respectively. In this study, we investigated whether an endogenous ear-EEG-based BCI with reasonable performance can be implemented in online environments that mimic real-world scenarios. To this end, we used three different mental tasks, i.e., mental arithmetic, word association, and mental singing, and performed BCI experiments with fourteen subjects on three different days to investigate not only the reliability of a real-time endogenous ear-EEG-based BCI, but also its test-retest reliability. The mean online classification accuracy was almost 70%, which was equivalent to a marginal accuracy for a practical two-class BCI (70%), demonstrating the feasibility of using ear-EEG for the development of real-time endogenous BCIs, but further studies should follow to improve its performance enough to be used for practical ear-EEG-based BCI applications.
Many researchers have suggested evaluation methods and Torsades de Pointes (TdP) metrics to assess the proarrhythmic risk of a drug based on the in silico simulation, as part of the Comprehensive in-vitro Proarrhythmia Assay (CiPA) project. In the previous study, we validated the robustness of 12 in silico features using the ordinal logistic regression (OLR) model by comparing the classification performances of metrics according to the in-vitro experimental datasets used; however, the OLR model using 12 in silico features did not provide desirable results. This study proposed a convolutional neural network (CNN) model using the variability of promising in silico TdP metrics hypothesizing that the variability of in silico features based on beats has more information than the single value of in silico features. We performed the action potential (AP) simulation using a human ventricular myocyte model to calculate seven in silico features representing the electrophysiological cell states of drug effects over 1,000 beats: qNet, qInward, intracellular calcium duration at returning to 50% baseline (CaD50) and 90% baseline (CaD90), AP duration at 50% repolarization (APD50) and 90% repolarization (APD90), and dVm/dtMax_repol. The proposed CNN classifier was trained using 12 train drugs and tested using 16 test drugs among CiPA drugs. The torsadogenic risk of drugs was classified as high, intermediate, and low risks. We determined the CNN classifier by comparing the classification performance according to the variabilities of seven in silico biomarkers computed from the in silico drug simulation using the Chantest dataset. The proposed CNN classifier performed the best when using qInward variability to classify the TdP-risk drugs with 0.94 AUC for high risk and 0.93 AUC for low risk. In addition, the final CNN classifier was validated using the qInward variability obtained after merging three in-vitro datasets, but the model performance decreased to a moderate level of 0.75 and 0.78 AUC. These results suggest the need for the proposed CNN model to be trained and tested using various types of drugs.
Heart-sound auscultation is one of the most widely used approaches for detecting cardiovascular disorders. Diagnosing abnormalities of heart sound using a stethoscope depends on the physician's skill and judgment. Several studies have shown promising results in automatically detecting cardiovascular disorders based on heart-sound signals. However, the accuracy performance needs to be enhanced as automated heart-sound classification aids in the early detection and prevention of the dangerous effects of cardiovascular problems. In this study, an optimal heart-sound classification method based on machine learning technologies for cardiovascular disease prediction is performed. It consists of three steps: pre-processing that sets the 5 s duration of the PhysioNet Challenge 2016 and 2022 datasets, feature extraction using Mel frequency cepstrum coefficients (MFCC), and classification using grid search for hyperparameter tuning of several classifier algorithms including k-nearest neighbor (K-NN), random forest (RF), artificial neural network (ANN), and support vector machine (SVM). The five-fold cross-validation was used to evaluate the performance of the proposed method. The best model obtained classification accuracy of 95.78% and 76.31%, which was assessed using PhysioNet Challenge 2016 and 2022, respectively. The findings demonstrate that the suggested approach obtained excellent classification results using PhysioNet Challenge 2016 and showed promising results using PhysioNet Challenge 2022. Therefore, the proposed method has been potentially developed as an additional tool to facilitate the medical practitioner in diagnosing the abnormality of the heart sound.
As part of the Comprehensive in vitro Proarrhythmia Assay initiative, methodologies for predicting the occurrence of drug-induced torsade de pointes via computer simulations have been developed and verified recently. However, their predictive performance still requires improvement. Herein, we propose an artificial neural networks (ANN) model that uses nine multiple input features, considering the action potential morphology, calcium transient morphology, and charge features to further improve the performance of drug toxicity evaluation. The voltage clamp experimental data for 28 drugs were augmented to 2,000 data entries using an uncertainty quantification technique. By applying these data to the modified O'Hara Rudy in silico model, nine features (dVm/dtmax, APresting, APD90, APD50, Caresting, CaD90, CaD50, qNet, and qInward) were calculated. These nine features were used as inputs to an ANN model to classify drug toxicity into high-risk, intermediate-risk, and low-risk groups. The model was trained with data from 12 drugs and tested using the data of the remaining 16 drugs. The proposed ANN model demonstrated an AUC of 0.92 in the high-risk group, 0.83 in the intermediate-risk group, and 0.98 in the low-risk group. This was higher than the classification performance of the method proposed in previous studies.
Electrocardiograms (ECGs) are widely used for diagnosing cardiac arrhythmia based on the deformation of signal shapes due to changes in various heart diseases. However, these abnormal signs may not be observed in some 12 ECG channels, depending on the location, the heart shape, and the type of cardiac arrhythmia. Therefore, it is necessary to closely and comprehensively observe ECG records acquired from 12 channel electrodes to diagnose cardiac arrhythmias accurately. In this study, we proposed a clustering algorithm that can classify persistent cardiac arrhythmia as well as episodic cardiac arrhythmias using the standard 12-lead ECG records and the 2D CNN model using the time-frequency feature maps to classify the eight types of arrhythmias and normal sinus rhythm. The standard 12-lead ECG records were provided by China Physiological Signal Challenge 2018 and consisted of 6877 patients. The proposed algorithm showed high performance in classifying persistent cardiac arrhythmias; however, its accuracy was somewhat low in classifying episodic arrhythmias. If our proposed model is trained and verified using more clinical data, we believe it can be used as an auxiliary device for diagnosing cardiac arrhythmias.
Arrhythmias, Cardiac/classification , Electrocardiography/methods , Algorithms , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/physiopathology , Diagnosis, Computer-Assisted , Female , Humans , Male , Models, Statistical , Neural Networks, Computer
It is well known that cardiac electromechanical delay (EMD) can cause dyssynchronous heart failure (DHF), a prominent cardiovascular disease (CVD). This work computationally assesses the conductance variation of every ion channel on the cardiac cell to give rise to EMD prolongation. The electrical and mechanical models of human ventricular tissue were simulated, using a population approach with four conductance reductions for each ion channel. Then, EMD was calculated by determining the difference between the onset of action potential and the start of cell shortening. Finally, EMD data were put into the optimized conductance dimensional stacking to show which ion channel has the most influence in elongating the EMD. We found that major ion channels, such as L-type calcium (CaL), slow-delayed rectifier potassium (Ks), rapid-delayed rectifier potassium (Kr), and inward rectifier potassium (K1), can significantly extend the action potential duration (APD) up to 580 ms. Additionally, the maximum intracellular calcium (Cai) concentration is greatly affected by the reduction in channel CaL, Ks, background calcium, and Kr. However, among the aforementioned major ion channels, only the CaL channel can play a superior role in prolonging the EMD up to 83 ms. Furthermore, ventricular cells with long EMD have been shown to inherit insignificant mechanical response (in terms of how strong the tension can grow and how far length shortening can go) compared with that in normal cells. In conclusion, despite all variations in every ion channel conductance, only the CaL channel can play a significant role in extending EMD. In addition, cardiac cells with long EMD tend to have inferior mechanical responses due to a lack of Cai compared with normal conditions, which are highly likely to result in a compromised pump function of the heart.
Myocardial fibrosis is an integral component of most forms of heart failure. Clinical and computational studies have reported that spatial fibrosis pattern and fibrosis amount play a significant role in ventricular arrhythmogenicity. This study investigated the effect of the spatial distribution of fibrosis and fibrosis amount on the electrophysiology and mechanical performance of the human ventricles. Seventy-five fibrosis distributions comprising diffuse, patchy, and compact fibrosis types that contain 10-50% fibrosis amount were generated. The spatial fibrosis distribution was quantified using the fibrosis entropy (FE) metric. Electrical simulations under reentry conditions induced using the S1-S2 protocol were conducted to investigate the fibrosis arrhythmogenicity. We also performed mechanical simulations to examine the influence of the fibrosis amount and the spatial distribution of fibrosis on the pumping efficacy of the LV. We observed that the mean FE of the compact type is the largest among the three types. The electrical simulation results revealed that the ventricular arrhythmogenicity of diffuse fibrosis depends on the fibrosis amount and marginally on the spatial distribution of fibrosis. Meanwhile, the ventricular arrhythmogenicity of the compact and patchy fibrosis pattern is more reliant on the spatial distribution of fibrosis than on the fibrosis amount. The average number of phase singularities (PSs) in the compact fibrosis pattern was the highest among the three patterns of fibrosis. The diffuse type of fibrosis has the lowest average number of PSs than that in the patchy and compact fibrosis. The reduction in the stroke volume (SV) showed high influence from the electrical instabilities induced by the fibrosis amount and pattern. The compact fibrosis exhibited the lowest SV among the three patterns except in the 40% fibrosis amount. In conclusion, the fibrosis pattern is as crucial as the fibrosis amount for sustaining and aggravating ventricular arrhythmogenesis.
The pulse arrival time (PAT), the difference between the R-peak time of electrocardiogram (ECG) signal and the systolic peak of photoplethysmography (PPG) signal, is an indicator that enables noninvasive and continuous blood pressure estimation. However, it is difficult to accurately measure PAT from ECG and PPG signals because they have inconsistent shapes owing to patient-specific physical characteristics, pathological conditions, and movements. Accordingly, complex preprocessing is required to estimate blood pressure based on PAT. In this paper, as an alternative solution, we propose a noninvasive continuous algorithm using the difference between ECG and PPG as a new feature that can include PAT information. The proposed algorithm is a deep CNN-LSTM-based multitasking machine learning model that outputs simultaneous prediction results of systolic (SBP) and diastolic blood pressures (DBP). We used a total of 48 patients on the PhysioNet website by splitting them into 38 patients for training and 10 patients for testing. The prediction accuracies of SBP and DBP were 0.0 ± 1.6 mmHg and 0.2 ± 1.3 mmHg, respectively. Even though the proposed model was assessed with only 10 patients, this result was satisfied with three guidelines, which are the BHS, AAMI, and IEEE standards for blood pressure measurement devices.
Blood Pressure Determination , Blood Pressure , Databases, Factual , Heart Rate , Machine Learning , Models, Cardiovascular , Photoplethysmography , Humans
Many studies have revealed changes in specific protein channels due to physiological causes such as mutation and their effects on action potential duration changes. However, no studies have been conducted to predict the type of protein channel abnormalities that occur through an action potential (AP) shape. Therefore, in this study, we aim to predict the ion channel conductance that is altered from various AP shapes using a machine learning algorithm. We perform electrophysiological simulations using a single-cell model to obtain AP shapes based on variations in the ion channel conductance. In the AP simulation, we increase and decrease the conductance of each ion channel at a constant rate, resulting in 1,980 AP shapes and one standard AP shape without any changes in the ion channel conductance. Subsequently, we calculate the AP difference shapes between them and use them as the input of the machine learning model to predict the changed ion channel conductance. In this study, we demonstrate that the changed ion channel conductance can be predicted with high prediction accuracy, as reflected by an F1 score of 0.985, using only AP shapes and simple machine learning.
Action Potentials/physiology , Cardiac Electrophysiology/methods , Ion Channels/metabolism , Machine Learning , Myocytes, Cardiac/metabolism , Neural Networks, Computer , Computer Simulation , Ion Channel Gating/physiology , Neurons/metabolism , Single-Cell Analysis/methods
